Investment company news brought to you by Citywire Financial Publishers Limited.
Citywire news
4 December 2018
Smithson, star fund manager Terry Smith’s new global smaller companies investment trust, releases some details of its 29 investments, which include a stake in British property portal Rightmove.
4 December 2018
‘The cities that will be winners from a hard Brexit are Berlin, Paris, Amsterdam and Dublin, and we have exposure to them,’ says fund manager Jeff O’Dwyer as three-year-old investment trust nears full deployment and achieves its dividend target.
30 November 2018
The Brexit uncertainty plaguing real estate investment trusts (Reit) underlined by decision of care home investor Impact Healthcare to postpone £150 million fund raise.
30 November 2018
Templeton Emerging Markets introduces dividend reinvestment plan to enable shareholders to plough back investment trust's growing income into its shares and reduce their wide discount to asset value.
29 November 2018
Shares in shopping centre owner slump 39% after a consortium led by its deputy chairman John Whittaker drop acquisition plans prompting group to warn it would cut its dividend.
28 November 2018
Lindsell Train fund manager Nick Train turns to staggering long-term performance of McDonald’s to justify why once again he has not made changes to his high-performing, £235 million portfolio.
28 November 2018
Political risk remains high but with plans to move back to the UK and after strong half-year results there are other reasons to like the 5%-yielding, £2.9 billion listed, social infrastructure fund.
28 November 2018
Dale Nicholls, manager of £1.1 billion Fidelity China Special Situations trust, has lifted his weighting in social media and gaming giant to 15% believing it will not be hurt by increased regulation.
27 November 2018
TwentyFour Income Fund, a 6% investment company focused on mortgage bonds and other asset-backed securities, raising money to take advantage of a ‘significant opportunity’ in distressed bond markets.
26 November 2018
Listed life sciences fund, the second-best performing investment trust this year, announces a 32.5% half-year return and adds protein specialist OMass Therapeutics to its portfolio.
